Overview
Shares of Hims & Hers Health opened lower in pre-market trading, down 4.19% to $24, extending a multi-session decline that began after the telehealth company released first-quarter 2026 results that missed expectations and simultaneously announced a planned convertible notes offering. The twin developments - a sizeable earnings miss and a dilutive capital-raising move - have driven intensified investor selling amid an already fragile market environment.
Quarterly results and business pivot
For Q1 2026, Hims & Hers reported earnings per share of -$0.40, compared with a consensus forecast of $0.01. Revenue for the period totaled $608 million, short of the $616.5 million analysts had expected. The company recorded a net loss of $92.1 million for the quarter, a notable reversal from net income of $49.5 million in the same quarter the prior year. Management attributed part of the year-over-year swing to the company’s deliberate shift away from lower-cost compounded weight-loss medications toward branded GLP-1 products.
Results were also affected by one-time items, including $33.5 million in non-recurring restructuring charges tied to changes in the U.S. weight-loss offering. The quarter further reflected fair value losses on certain financial liabilities and equity securities, contributing to overall pressure on the bottom line.
Planned convertible offering and intended use of proceeds
Adding to investor concerns, Hims & Hers said it intends to offer $300 million of convertible senior notes due 2032 in a private placement to qualified institutional buyers. Initial purchasers will have an option to buy an additional $45 million in notes. Management indicated that part of the proceeds would support international expansion efforts, including the proposed acquisition of Eucalyptus, which the company expects to close in mid-2026.
The proposed notes financing introduces dilution risk and was a proximate cause of the pre-market selling pressure, coming on top of weaker-than-expected quarterly operating results.
Analyst reactions and Street divergence
Analyst reactions to the quarter and the company’s strategic transition have been mixed. Bank of America trimmed its price target to $30 from $32 while retaining a Neutral rating. JPMorgan lowered its target to $33 from $35 but kept an Overweight rating. In contrast, Canaccord raised its target to $32 from $30 and maintained a Buy rating. The split among analysts highlights differing views on the company’s prospects after the product mix pivot.
Citi analysts described the company’s near-term outlook as "mixed," characterizing Q1 as a "transition" period as Hims & Hers reduces its reliance on compounded GLP-1 offerings. The lack of meaningful news from telehealth peers Teladoc Health and GoodRx meant there was no sector-wide catalyst to offset company-specific weakness.
Market backdrop
The broader equity market provided little support. On the day of the report the S&P 500 was down -1.24%, the Dow Jones Industrial Average fell -1.07%, and the NASDAQ declined -1.54%. This risk-off mood in equities tends to magnify selling pressure on growth-oriented names, including telehealth companies such as Hims & Hers.
Management comment and outlook
CEO Andrew Dudum said the company views 2026 as a pivotal year, asserting that "2026 is a defining year for Hims & Hers" and that "as we exit the first quarter, our domestic business is accelerating, we’re expanding into new categories and countries." Despite that message, investors are weighing margin compression, the surprise net loss, the dilutive nature of the convertible offering, and a soft macro environment simultaneously.
With those factors converging, the stock remained under meaningful selling pressure in pre-market trading as market participants reassessed the company’s near-term performance and financing plan.
Key points
- Hims & Hers reported a Q1 2026 EPS of -$0.40 and revenue of $608 million, missing analyst expectations and producing a net loss of $92.1 million versus net income of $49.5 million a year earlier.
- The company plans a $300 million convertible senior notes offering due 2032, with an initial purchaser option for an extra $45 million, aimed partly at supporting international expansion and the proposed Eucalyptus acquisition expected to close in mid-2026.
- Analysts on the Street are split on the company’s post-pivot prospects, and a risk-off broader market environment intensified selling pressure on the stock.
Risks and uncertainties
- Execution risk from the product mix shift - the company’s pivot away from compounded weight-loss drugs toward branded GLP-1s coincided with margin compression and a surprise quarterly net loss, creating uncertainty about near-term profitability (impacts telehealth and healthcare sectors).
- Financing and dilution risk - the proposed $300 million convertible notes offering introduces potential dilution and has contributed to negative investor sentiment (impacts company equity holders and credit markets).
- Market risk - a weak macro and risk-off market backdrop amplified selling pressure on growth-oriented stocks, leaving no sector-level support to stabilize the company’s share price (impacts broader equities and growth-sector investors).